BRIEF published on 08/08/2025 at 23:35, 3 months 27 days ago La FDA approuve le système Genio® de Nyxoah pour le traitement de l'apnée obstructive du sommeil Approbation De La FDA Nyxoah Apnée Obstructive Du Sommeil Commercialisation Aux États-Unis Système Genio
PRESS RELEASE published on 08/08/2025 at 23:30, 3 months 27 days ago Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea Nyxoah receives FDA approval for Genio System, advancing OSA treatment with bilateral stimulation and leadless technology. U.S. commercialization launched FDA Approval Nyxoah Obstructive Sleep Apnea Neuromodulation Genio System
BRIEF published on 07/28/2025 at 22:10, 4 months 7 days ago Nyxoah’s DREAM Study Data Featured in Clinical Journal Obstructive Sleep Apnea DREAM Study Clinical Outcomes Genio® System Patient Satisfaction
BRIEF published on 07/28/2025 at 22:10, 4 months 7 days ago Les données de l'étude DREAM de Nyxoah présentées dans une revue clinique Résultats Cliniques Apnée Obstructive Du Sommeil Étude DREAM Système Genio® Satisfaction Des Patients
PRESS RELEASE published on 07/28/2025 at 22:05, 4 months 7 days ago Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Nyxoah's DREAM pivotal study data on Genio system for OSA treatment published in Journal of Clinical Sleep Medicine. Study shows high patient satisfaction & improved quality of life Sleep Medicine Nyxoah Genio System DREAM Pivotal Study OSA Treatment
BRIEF published on 05/14/2025 at 07:05, 6 months 22 days ago Nyxoah Reports First Quarter 2025 Financial and Operating Results Financial Results FDA Approval Nyxoah Q1 2025 Genio System
BRIEF published on 05/14/2025 at 07:05, 6 months 22 days ago Nyxoah publie ses résultats financiers et opérationnels du premier trimestre 2025 Résultats Financiers Approbation De La FDA Nyxoah Système Genio T1 2025
PRESS RELEASE published on 05/14/2025 at 07:00, 6 months 22 days ago Nyxoah Reports First Quarter Financial and Operating Results Nyxoah reports financial and operating results for the first quarter of 2025, including progress towards FDA PMA approval for the Genio® system. Revenue €1.1 million. Cash position €63.0 million Financial Results FDA Approval Operating Highlights Nyxoah Genio® System
BRIEF published on 04/08/2025 at 07:05, 7 months 27 days ago Nyxoah informe sur le processus d'approbation du système Genio par la FDA Technologie Médicale Approbation De La FDA Nyxoah Apnée Obstructive Du Sommeil Système Genio
BRIEF published on 04/08/2025 at 07:05, 7 months 27 days ago Nyxoah Updates on FDA Approval Process for Genio System FDA Approval Medical Technology Nyxoah Obstructive Sleep Apnea Genio System
Published on 12/05/2025 at 02:35, 6 hours 40 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 8 hours 15 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 10 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 15 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:05, 10 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 30 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 30 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 33 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 15 hours 1 minute ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 15 hours 15 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
